PTPN21

Across TCGA pan-cancer cohorts, PTPN21 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PTPN21 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PTPN21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPN21 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

SCLC, OV, and LUAD are the cancer types where PTPN21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	42	view →
OV	OS	Median	II,III,IV	0.291	0.693	.012	18	view →
LUAD	OS	Median	II,III,IV	0.079	0.709	<.001	18	view →
UCEC	DFS	Median	All	0.806	0.629	.002	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LGG	OS	Median	All	0.255	0.799	.001	9	view →
STAD	DFS	Median	III,IV	0.871	0.328	.026	8	view →
SARC	OS	Median	All	0.164	0.827	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PTPN21–SCLC (OS)

Open the SCLC breakdown →